Aims: Studies have shown that bortezomib retreatment is effective in relapsed/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE ® OBservational Study (eVOBS) study assessed bortezomibbased therapies for patients with MM in everyday practice. Here, we report on those patients receiving retreatment with bortezomib.
| INTRODUCTION
Multiple myeloma (MM) is an incurable disease with a high incidence rate in elderly people. 1 The disease typically follows a relapsing course, with many patients requiring multiple lines of therapy. 2 The choice of treatment for relapsed and/or refractory (RR) MM may be influenced by several factors, including patients' prior regimen(s), comorbidities, disease characteristics at relapse, prior treatmentrelated toxicities, and duration of prior remission. [3] [4] [5] One of the mainstays of treatment for RRMM is the proteasome inhibitor bortezomib, with numerous phase 2 and 3 studies clearly showing therapeutic effectiveness in this patient population. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In Europe, bortezomib is currently approved for progressive MM in patients who have received ≥1 prior therapy (alone or in combination with pegylated liposomal doxorubicin or dexamethasone) and who have already undergone or are unsuitable for hematopoietic stem cell transplantation (HSCT). It is also approved as a treatment for patients with previously untreated MM who are ineligible for high-dose chemotherapy with HSCT (in combination with melphalan and prednisone), or as induction treatment prior to high-dose chemotherapy with HSCT (in combination with dexamethasone, or with dexamethasone and thalidomide). 21 Bortezomib is a recommended treatment option for RRMM. 22 For patients with MM who receive a finite course of bortezomib (ie, not receiving maintenance treatment), their disease may remain sensitive to bortezomib-based therapy at relapse.
Retreatment with bortezomib is, therefore, a viable option for patients with progressive disease (PD), either as a subsequent or later line of therapy after initial bortezomib treatment. A number of retrospective studies, [23] [24] [25] [26] [27] [28] [29] [30] [31] prospective clinical trials, 32, 33 and a recent meta-analysis 34 have demonstrated the viability of retreatment with bortezomib, all showing bortezomib-based retreatment to be efficacious and tolerable. 35 On the basis of the prospective clinical study by Petrucci et al, 32 the indication for bortezomib in the US was expanded in late 2014 to include retreatment in patients who have previously responded to bortezomib and who have relapsed at least 6 months after completing prior bortezomib treatment. 36 While the efficacy and safety of bortezomib-based therapies for retreatment have been shown in the highly controlled clinical trial setting, these findings may not reflect those observed in routine medical practice, where the patient population can differ substantially from that selected by strict clinical trial entry criteria. To date, however, data on the use of bortezomib retreatment in the "realworld" oncology practice setting are limited. To address this gap, we conducted a sub-analysis of the prospective, international, noninterventional, electronic VELCADE OBservational Study (eVOBS) that was designed to study the efficacy and safety of bortezomibbased therapies for MM in real-world medical practice. 37 In our sub-analysis, we examined the efficacy and safety of bortezomibbased retreatment for relapsed MM during the monitoring period of eVOBS. All patients provided written informed consent in accordance with local legislation.
| Objectives and endpoints
The overall objective of eVOBS was to evaluate the clinical outcomes associated with bortezomib-based therapies in real-world medical practice. 37 The objective of the present sub-analysis was to evaluate the efficacy and safety of bortezomib-based retreatment in patients with progressive MM following initial bortezomib-based treatment during the prospective observational period of eVOBS. 
| Statistical analyses
All time-to-event endpoints were analyzed using Kaplan-Meier and best response to bortezomib. The two-sided log-rank test was used to assess the significance of any differences between the stratified data; the conventional significance threshold of 0.05 was used across all analyses. As described in Terpos et al, missing data were not substituted nor imputed. 37 Statistical analysis was performed using SAS version 9.2. Creatinine clearance data missing for three patients.
c
Including initial bortezomib.
3 | RESULTS
| Patients
In total, 1573 patients who initiated bortezomib treatment for MM, at any of the 162 surveyed centers, were enrolled into the eVOBS registry. Due to concerns about data quality, 700 patients enrolled in Russia were excluded from the primary study analysis, leaving 873 evaluable patients. Demographics and baseline characteristics for the entire eVOBS population have been reported previously.
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Of the 873 patients with MM who received bortezomib-based therapy during the 3-year prospective observational phase, 96 (11%) underwent retreatment with bortezomib for PD during this period.
The number of retreated patients enrolled by country was Belgium (n = 29), Brazil (n = 17), France (n = 11), Greece (n = 26), Spain (n = 4), Sweden (n = 4), and Turkey (n = 5). Although patients were also enrolled into the eVOBS study at clinics in Canada, none underwent bortezomib retreatment for PD during the prospective observational phase.
Demographics and baseline characteristics for the 96 retreated patients are summarized in In the retreatment population, the median age (62 years) and proportion of males (53%) were both slightly lower than in the overall population (65 years and 58%, respectively). Other bortezomib-dexamethasone combinations 12 (13) 5 (5) Bortezomib-thalidomide (including dexamethasone combinations) 7 (7) 6 (6) Bortezomib-prednisone 3 (3) 4 (4) Other bortezomib combinations 1 (1) 3 (3) Bortezomib-lenalidomide 2 (2) 19 (20) Dose of bortezomib received at initiation, n (%) Includes patient withdrawal, lost to follow-up, and those with unreported reasons.
| Bortezomib retreatment
The majority of patients undergoing bortezomib retreatment received this therapy as their fourth or fifth line ( Table 2 ). The most common bortezomib-based regimens received at initial treatment and at retreatment were bortezomib plus dexamethasone (53% and 41%, respectively) and bortezomib monotherapy (each 21%) ( Table 2 ).
There was a notable increase in the use of bortezomib plus lenalidomide combination therapies between initial bortezomib treatment (2%) and retreatment (20%).
In total, 91 (95%) patients had received an alternative treatment for MM between initial bortezomib and bortezomib retreatment. Of these, 49 (51%) had one alternative treatment, 25 (26%) had two, 12 Table 2) . These were mostly, if not all, IV administrations, since the study was conducted during a time that IV infusion was the only approved mode of administration. Patients received a median (range) of 6 (1-24) bortezomib cycles during initial bortezomib treatment, compared with 4 (1-12) cycles at retreatment. In bortezomib-retreated patients, discontinuations during initial bortezomib treatment and retreatment, respectively, were predominantly due to treatment completion (32% vs 19%), discontinuation due to AEs (20% vs 19%), and PD (15% vs 34%) ( Table 2 ).
| Best response to bortezomib retreatment
Criteria used for response assessment in the subset of bortezomibretreated patients were M-protein reduction (n = 35, 36%), EBMT response criteria (n = 33, 34%), other (not specified) criteria (n = 24, 25%), and SWOG response criteria (n = 4, 4% We investigated factors that may influence response to retreatment. In total, 68% of patients who had achieved CR/nCR with initial bortezomib achieved ≥PR on retreatment; this figure was 39%
in patients who had achieved PR and 20% in patients who had achieved ≤MR with initial bortezomib (P = 0.0022; two-sided log-rank test). In patients who had received one or two prior therapies, 70%
achieved ≥PR at retreatment, compared with 48% for three prior therapies and 39% for four or more prior therapies (Figure 1 ; P = 0.055; two-sided log-rank test). There was no significant difference in the ≥PR rate to bortezomib retreatment in patients stratified by a TFI of <6 versus ≥6 months between end of previous treatment line and bortezomib initiation. Of the 96 patients receiving bortezomib retreatment, 12 received a second retreatment with bortezomib following PD, of whom one patient achieved CR and one achieved PR.
| Survival outcomes
In bortezomib-retreated patients, median follow-up from the start of There was no statistically significant difference in OS (P = 0.0723; two-sided log-rank test), or PFS (P = 0.3062; two-sided log-rank test), Figure 4 ; two-sided log-rank test) according to the number of lines of therapy received prior to bortezomib retreatment.
FIGURE 3
Kaplan-Meier analysis of (A) progression-free survival and (B) overall survival from the start of bortezomib retreatment, stratified by treatment-free interval between initial bortezomib treatment and subsequent line of therapy. OS, overall survival; PD, progressive disease; PFS, progression-free survival; TFI, treatment-free interval
Kaplan-Meier analysis of (A) progression-free survival and (B) overall survival after bortezomib retreatment, stratified by best response to retreatment. CR, complete response; MR, minimal response; nCR, near complete response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response
| Safety profile during retreatment
Of the 96 patients who underwent retreatment with bortezomib post-PD, 74 (77%) reported AEs (Table 3 ). In total, 41 (43%) patients experienced grade ≥3 AEs, of which thrombocytopenia (5%) and anemia (4%) were most common. Serious adverse events (SAEs) were experienced by 39 (41%) patients, including pneumonia (6%), death (3%), disease progression (3%), and skeletal injury (3%). Eighteen (19%) patients discontinued bortezomib retreatment due to AEs, including neuropathy (n = 3), bone pain (n = 2), disease progression (n = 2), neutropenia (n = 2), and pneumonia (n = 2). Eight (8%) patients died during retreatment. 
| Peripheral neuropathy

| DISCUSSION
Results from this analysis of 96 patients retreated with bortezomib during the prospective observational phase of the eVOBS study suggest that bortezomib retreatment is feasible in patients with RRMM in routine medical practice with a safety profile consistent with previous studies of bortezomib. 21 Over half of the retreated patients had advanced stage III MM at initial diagnosis, and the patient population, as a whole, was heavily pretreated before receiving bortezomib retreatment (median of four prior lines of therapy). Our findings compare favorably with those from the bortezomib pivotal phase 2 study, in which the ≥PR rate was 40% in 130 patients who had received a median of 2, rather than 4, prior lines of therapy, 32 and are also in line with the results of other previous prospective and retrospective clinical studies. [23] [24] [25] [26] [27] 29, 33, 34 The majority (77%) of patients included in this analysis were enrolled at clinics in countries within the European Union. Most of these patients received bortezomib-dexamethasone or bortezomib monotherapy for initial bortezomib treatment, and bortezomib retreatment within eVOBS. These approaches are in line with the current European approval status of bortezomib 21 and present treatment practices for RRMM in Europe. 22 
FIGURE 4
Kaplan-Meier analysis of overall survival from the start of retreatment, stratified by number of prior lines of therapy Of the 96 patients included in this study who were eventually retreated with bortezomib, 75% achieved ≥PR after their initial bortezomib treatment, including 44% CR/nCR. These rates are slightly higher than the 69% ≥PR rate and 37% CR/nCR rate observed in the overall eVOBS study population following initial bortezomib-based treatment. 37 Although the populations were generally similar, differences in patient and baseline disease characteristics between the overall study population and the retreated population may have contributed to these observed results. 37 It is also likely that patients who had initially responded well to bortezomib were preferentially chosen for retreatment, resulting in a population with a higher initial response rate.
In our retreated cohort, 46% of patients achieved ≥PR with bortezomib retreatment, including 15% CR/nCR. The ≥PR rate with bortezomib retreatment reported here is comparable with overall response rates reported with bortezomib retreatment in previous prospective clinical trials, 32,33 a retrospective case series, 27 and a metaanalysis, 34 but is slightly lower than the 60% reported by Ahn et al, in their retrospective study. 31 In the latter study, however, patients had received a median of two prior therapies, and only those who had relapsed or progressed ≥6 months after the previous bortezomib therapy were included. 31 Despite a higher response rate, median PFS was comparable, at 5.5 months (95% CI: 4.2-6.8). Generally, though, due to differences in study design (eg, different criteria for response assessment and patient inclusion criteria/patient populations), interstudy comparisons of response rates should be interpreted with caution.
The ≥PR rates observed with bortezomib retreatment in this study are encouraging, considering the advanced disease stage and heavily pretreated nature of the retreated population. This is consistent with previous studies demonstrating that bortezomib retreatment is feasible in later lines of therapy and can produce responses in a considerable proportion of patients. 24, 25, 27, 33, 41 The observed decrease in ≥PR rate between initial bortezomib and bortezomib retreatment is consistent with the progressive nature of MM. dynamics. [42] [43] [44] The CoMMpass trial is currently in progress and may suggest the optimal genotypic environment for bortezomib retreatment. 45 In addition, there was a non-statistically significant trend for a higher ≥PR rate in patients who had undergone fewer therapies prior to retreatment. While no significant difference in ≥PR rate was observed between patients who had a TFI ≥6 or <6 months in this study, higher overall response rates 24 and longer OS 31 in patients with a longer TFI have been reported previously. 23 Limitations to the survey approach used for data collection in the eVOBS study include the variable criteria used for response assessment, which may have impacted the efficacy findings. However, this is the reality of clinical care across sites and countries, and although a substantial proportion of responses were assessed by M-protein or non-specified criteria, the overall eVOBS study population (N = 873)
showed no substantial impact on survival distributions by best response (EBMT criteria vs other methods). 37 Additionally, no formal sample size calculations were performed for the study population, which limited the ability to detect relevant changes pre-and posttreatment.
Median PFS from the start of initial bortezomib (11.4 months) was longer than from the start of retreatment (6.4 months), in accordance with the disease course of an increasingly aggressive cancer in later lines of therapy. 2 The median OS of 17.6 months from the start of bortezomib retreatment observed in this study is comparable with that reported in a recent meta-analysis (16.6 months). The safety profile observed with bortezomib retreatment in this study is consistent with that known for bortezomib in RRMM, 12, 13 and with prior clinical studies of bortezomib retreatment, 25, 28, 32 and in a bortezomib retreatment meta-analysis. 34 The most common AEs reported with bortezomib retreatment in this study were hematologic-, gastrointestinal-, and neurologic-related toxicities.
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Notably, there was no apparent increase in PN incidence at bortezomib retreatment versus initial bortezomib treatment. Although we did not document reversibility of PN, previous studies have shown that bortezomib-induced PN is manageable and reversible in RRMM patients. 46 In summary, the activity of bortezomib retreatment in this non- IV infusion. 47 The role of second-generation proteasome inhibitors in retreatment after an initial bortezomib course should also be investigated, as well as the potential clinical contribution of other combinatory agents in that setting, such as immunomodulatory therapies, histone deacetylase inhibitors, and chemotherapy.
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